Skip to content

Clinical Study on the Combination of Lumaiyifei Formula and Immune Checkpoint Inhibitors to Improve the Treatment Response Rate in Advanced Non-Small Cell Lung Cancer

Clinical Study on the Combination of Lumaiyifei Formula and Immune Checkpoint Inhibitors in Enhancing Treatment Response Rate in Advanced Non-Small Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000614
Enrollment
Unknown
Registered
2025-03-29
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Control group:Chinese herbal placebo + Immune Checkpoint Inhibitors ± Chemotherapy
Treatment Group:Lumaiyifei Formula + Immune Checkpoint Inhibitors ± Chemotherapy

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with advanced non-small cell lung cancer (including stage IV and unresectable stage III) based on pathological and imaging findings; 2. Age =18 years and =75 years with no gender restrictions; 3. Patients planned to receive ICIs treatment; 4. Performance status score (ECOG PS) =2; 5. Normal major organ function: absolute neutrophil count >1.5×10?/L platelet count >80×10?/L hemoglobin >90 mg/dL; normal liver and kidney function; 6. Able to understand agree to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of any active lung disease (including interstitial pneumonia radiation pneumonitis clinically symptomatic active pneumonia or severe pulmonary dysfunction) autoimmune disease or a history of autoimmune disease (including but not limited to autoimmune hepatitis interstitial pneumonia etc.); 2. Any medical condition with an expected survival of less than 2 months; 3. History of uncontrolled psychiatric disorders; 4. Pregnant or lactating patients; 5. Known allergy to the traditional Chinese medicine components used in this study; 6. Long-term use of immunosuppressive drugs; 7. Symptomatic brain metastases.

Design outcomes

Primary

MeasureTime frame
Disease control rate;

Secondary

MeasureTime frame
Quality of life;Overall survival;Progress free survival;MD Anderson Traditional Chinese Medicine (TCM) Clinical Symptoms;Lung immune prognostic index;Peripheral blood immune function;

Countries

China

Contacts

Public ContactYichao Wang

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

wangyc2019128@163.com18801765140

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026